LAG‐3, a third‐generation ICP following PD‐1 and CTLA‐4, has attracted extensive attention, particularly after the U.S. Food and Drug Administration has approved the first LAG‐3‐targeting drug Relatlimab for its superior efficacy when used in combination with PD‐1 inhibitors compared to anti‐PD‐1 monotherapy in melanoma patients.[5] Previous studies have shown that 25–50% of patients with untreated non‐small cell lung cancer (NSCLC) are positive for LAG‐3 on tumor‐infiltrating lymphocytes (TILs),[4, 6] highlighting its potential therapeutic significance. This evidence concerns the gene LAG3 and melanoma.